---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000022"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:08:48.254336+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Stockholders approve 2.7M share increase under 2018 Equity Plan, re-elect all directors at annual meeting

## Summary
- All ten director nominees elected; John A. Orwin received 43.7M for vs 14.9M withheld.
- 2018 Equity Plan amended to add 2.7M authorized shares; vote 36.4M for, 22.1M against.
- Advisory say-on-pay passed with 55.8M for, 2.9M against, 42k abstain.
- Ernst & Young ratified as FY2024 auditor with 60.5M for, 2.2M against, 52k abstain.

## SEC filing metadata
- accession: 0001438533-24-000022
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/tvtx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000022
- JSON: https://secwatch.observer/filing/0001438533-24-000022.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000022.txt

## Key facts
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Approval of the Company’s 2018 Equity Incentive Plan, as amended at the 2024-05-08 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Election of Directors at the 2024-05-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2025 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2024-05-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm
- Shareholder Votes
  Travere Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2024-05-08 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2024-05-08
  source text: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000022/0001438533-24-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.